meropenem and Pleural-Effusion

meropenem has been researched along with Pleural-Effusion* in 4 studies

Other Studies

4 other study(ies) available for meropenem and Pleural-Effusion

ArticleYear
Severe case of pneumonia with pleural effusion in an immunocompromised woman due to
    BMJ case reports, 2019, Jan-31, Volume: 12, Issue:1

    Infections caused by fusobacteria have a wide clinical spectrum, and in certain patients, they can lead to severe systemic illness. We report the case of an immunocompromised young woman who presented with severe pneumonia complicated by parapneumonic pleural effusion, despite wide-spectrum antibiotic treatment.

    Topics: Adult; Anti-Bacterial Agents; Diagnosis, Differential; Empyema, Pleural; Female; Fusobacterium Infections; Fusobacterium necrophorum; Humans; Immunocompetence; Lemierre Syndrome; Meropenem; Pleural Effusion; Pneumonia; Treatment Outcome

2019
Clinical significance of positive Raoultella Ornithinolytica and Staphylococcus hominis cultures in a post lobectomy patient. A case report.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2018, 02-26, Volume: 88, Issue:1

    Raoultella Ornithinolytica (RO) is an encapsulated, Gram- negative, nonmotile aerobic rob which was reclassified from Klepsiella genus belonging in the family of Enterobacteriaceae. It is a rare human infection and few cases have been reported in post thoracotomy patients. Here we present a case of a left lower lobectomy patient that was complicated by pleural effusion and high fever with positive sputum cultures of Raoultella Ornithinolytica and positive pleural fluid cultures of Staphylococcus hominis. It is related with aquatic life poisoning. There are few cases reported and even fewer postoperatively. The infection is rare in human therefore the bacteria is still underreported.

    Topics: Aged; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Ciprofloxacin; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Male; Meropenem; Pleural Effusion; Postoperative Complications; Sputum; Staphylococcal Infections; Staphylococcus hominis; Treatment Outcome

2018
Campylobacter fetus bacteremia with purulent pleurisy in a young adult with primary hypogammaglobulinemia.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:11

    A 24-year-old man presented with fever and pleural effusion predominantly containing lymphocytes. Cultures of the pleural effusion and blood revealed Campylobacter fetus, and laboratory studies showed a low serum level of immunoglobulin. The patient was diagnosed with C. fetus pleuritis, bacteremia and primary hypogammaglobulinemia, and subsequent treatment with meropenem and immunoglobulin improved his condition. Although the underlying cause of the primary hypogammaglobulinemia remains unclear, the patient's status improved under immunoglobulin replacement therapy. C. fetus pleuritis is a rare infectious disease usually observed in immunocompromised hosts. We herein describe the first report of C. fetus pleuritis in a young adult with primary hypogammaglobulinemia.

    Topics: Agammaglobulinemia; Bacteremia; Campylobacter fetus; Campylobacter Infections; Empyema, Pleural; Humans; Immunization, Passive; Immunocompromised Host; Lung; Male; Meropenem; Pleural Effusion; Pleurisy; Radiography; Thienamycins; Young Adult

2014
[Pharmacokinetic study of penetration of meropenem into pleural effusion in patients with pleurisy].
    The Japanese journal of antibiotics, 2002, Volume: 55, Issue:1

    Complication by secondary infection is observed in not only bacterial pleurisy but also other pleurisy, and the appropriate administration of antibacterial agents is necessary. It is very important to secure a smooth penetration of systemically administered antibacterial agents to pleural effusion in infection therapy. In this study, we investigated the pharmacokinetics of a carbapenem antibiotic, meropenem (MEPM), in blood and pleural effusion in patients with an accumulation of pleural effusion caused by pleurisy, who underwent placement of an indwelling thoracic drain and received intravenous drip administration of MEPM for pneumonia or other respiratory tract infection. The blood pharmacokinetic parameters of MEPM after an intravenous drip administration of 0.5 g MEPM in six patients were: area under the blood concentration-time curve (AUCx), 37.9 +/- 6.2 (hr.mg/L); volume of distribution (Vd), 27.3 +/- 4.4 (L); total clearance (CLtotal), 13.4 +/- 1.8 (L/hr); elimination half life (t1/2), 0.50 +/- 0.08 (hr-1); and elimination rate constant (kel), 1.42 +/- 0.22 (hr). The pharmacokinetic parameters in pleural effusion were: AUCx, 35.7 +/- 7.1 (hr.mg/L); mean retention time (MRT), 5.00 +/- 3.25 (hr); variance of retention time (VRT), 29.9 +/- 44.6 (hr2); kel, 0.34 +/- 0.27 (hr-1); and t1/2, 3.14 +/- 2.36 (hr). The penetration rate calculated from the ratio of pleural concentration to blood concentration in each patient was 46.5 +/- 26.1%, showing good penetration comparable or superior to those of other antibacterial agents previously reported. From these results, it was suggested that MEPM was rapidly penetrated to the pleural effusion and was retained for a more prolonged time in the pleural effusion than in the blood of patients with accumulated pleural effusion, and it suggested the usefulness of MEPM in antibacterial therapy for patients with pleurisy causing accumulation of pleural effusion.

    Topics: Aged; Female; Humans; Male; Meropenem; Middle Aged; Pleural Effusion; Pleurisy; Thienamycins

2002